Biodexa Pharmaceuticals (BDRX) Non-Current Deffered Revenue (2018 - 2025)
Biodexa Pharmaceuticals (BDRX) posted Non-Current Deffered Revenue of $857957.2 for Q4 2025, down 29.25% sequentially from $1.2 million in Q2 2025, and down 48.82% YoY from $1.7 million in Q4 2024.
Biodexa Pharmaceuticals (BDRX) Non-Current Deffered Revenue (2018 - 2025) Analysis & Trends
Biodexa Pharmaceuticals has reported Non-Current Deffered Revenue for 4 years, with the latest figure at $857957.2 in Q4 2025.
- Quarterly Non-Current Deffered Revenue fell 48.82% year-over-year to $857957.2 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $857957.2 (down 48.82% YoY) and the FY2025 annual result came in at $850439.2, down 49.27% from the prior year.
- Non-Current Deffered Revenue declined to $857957.2 in Q4 2025 per BDRX's latest filing, from $1.2 million in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $2.0 million in Q2 2024 and troughed at $857957.2 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Biodexa Pharmaceuticals | 64,325.41 | -11.29 Mn | - | 857,957.20 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 857,957.20 |
| Jun 30, 2025 | 1.21 Mn |
| Dec 31, 2024 | 1.68 Mn |
| Jun 30, 2024 | 1.96 Mn |
| Jun 30, 2019 | -100,332.38 |
| Dec 31, 2018 | -603,493.83 |